MedTrace Logo

Rapip Study: Clinical Trial on Remifentanyl for Analgesia and Sedation of Ventilated Neonates and Infants

NCT00419601 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2010-06-25

No results posted yet for this study

Summary

It shall be investigated whether ventilated neonates and infants with a remifentanyl based analgesia and sedation can be extubated faster after discontinuation of the opioid infusion compared to neonates and infants with a fentanyl based analgesia and sedation.

Conditions

  • Mechanical Ventilation

Interventions

DRUG

Remifentanyl

Start dose:9 µg/kg/h Maximum dose: 30 µg/kg/h

DRUG

Fentanyl

start dose: 3 µg/kg/h Maximum dose: 10 µg/kg/h

Sponsors & Collaborators

Principal Investigators

  • Bernhard Roth, Prof. · Clinic for Paediatrics, University of Cologne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Max Age
60 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2010-04-30
Completion
2010-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00419601 on ClinicalTrials.gov